Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Vaginal Ring Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women

NCT02010593
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Dapivirine Vaginal Ring, Placebo Vaginal Ring
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 3, 2026, 8:35 AM EDT
Terminated Phase 4 Interventional

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse

NCT01092624
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Solifenacin, Placebo, Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex
Drug · Device
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 3, 2011 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

NCT02364882
View directory record Official record
Conditions
Female Sexual Health
Interventions
Sildenafil
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Sep 3, 2026, 8:35 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Assessing the Effects of a Topically Applied Cream to Clitoral Blood Flow

NCT01085981
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%, Topical study cream, GRAS cream
Drug
Lead sponsor
East Suburban Ob Gyn
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Vaginal Progesterone to Reduce the Risk of Another Preterm Birth

NCT00086177
View directory record Official record
Conditions
Pregnancy
Interventions
8% progesterone vaginal gel, Placebo Vaginal Gel
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
636 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
45
States / cities
Mobile, Alabama • Tucson, Arizona • Colton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Sep 3, 2026, 8:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

Vaginal Microbiota Transplant

NCT04046900
View directory record Official record
Conditions
Recurrent Bacterial Vaginosis
Interventions
Vaginal microbiome transplant, Oral Metronidazole, Sterile saline
Biological · Drug · Other
Lead sponsor
Douglas Kwon
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 3, 2026, 8:35 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effects of Combined Spinal Epidurals on Fever During Labor of First-Time Mothers

NCT00802646
View directory record Official record
Conditions
Vaginal Delivery
Interventions
saline, fentanyl/bupivacaine/epinephrine
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 34 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms

NCT02569697
View directory record Official record
Conditions
HIV
Interventions
HEC Placebo gel, Placebo Intravaginal Ring, Placebo Vaginal Film, Placebo Vaginal Insert
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

NCT02237950
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 2 Interventional Results available

LACTIN-V Study for Recurrent Bacterial Vaginosis

NCT02766023
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Lactobacillus crispatus CTV-05, Metronidazole, Placebo
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin

NCT03211156
View directory record Official record
Conditions
Vaginitis Gardnerella
Interventions
Amoxicillin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 3 Interventional Results available

The Vaginal Health Trial

NCT02516202
View directory record Official record
Conditions
Atrophy of Vagina, Menopause, Dyspareunia (Female)
Interventions
Vagifem, Replens, Placebo tablet, Placebo gel
Drug · Device · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 2 Interventional Results available

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

NCT02449902
View directory record Official record
Conditions
Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions
Estradiol, placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 3, 2026, 8:35 AM EDT
Terminated Phase 4 Interventional

Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery

NCT05317364
View directory record Official record
Conditions
Obstetric; Injury Pelvic Floor, Sexual Dysfunction, Anal Incontinence, Urinary Incontinence
Interventions
Estradiol 0.01% Vag Cream, Placebo vaginal cream
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery

NCT03040011
View directory record Official record
Conditions
Pelvic Organ Prolapse, Surgery, Postoperative Pain
Interventions
Dexamethasone, Bupivacaine, Bilateral Pudendal Nerve Block, Bilateral Levator Ani Muscle Injection, Saline
Drug · Procedure
Lead sponsor
Lauren Giugale, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 3, 2026, 8:35 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial

NCT00946088
View directory record Official record
Conditions
Pregnancy Complications
Interventions
Progesterone, Polyethylene glycol&hydrogenated vegetable oil.
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 3, 2026, 8:35 AM EDT
Not listed Phase 4 Interventional

Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair

NCT04573504
View directory record Official record
Conditions
Vaginal Laceration During Delivery
Interventions
Augmentin/Flagyl or Augmentin/Clindamycin, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 3, 2026, 8:35 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)

NCT02762617
View directory record Official record
Conditions
Healthy, HIV
Interventions
Tenofovir disoproxil fumarate intravaginal ring, Placebo intravaginal ring (IVR)
Drug
Lead sponsor
Marla Keller
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 3, 2026, 8:35 AM EDT
Withdrawn Phase 3 Interventional

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

NCT03619005
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Interventions
Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Huntsville, Alabama • San Diego, California • New London, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 2 Interventional Results available

Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women

NCT01230814
View directory record Official record
Conditions
Bacterial Vaginosis, Candidiasis, Trichomoniasis
Interventions
Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 5, 2014 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 3 Interventional Results available

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
prasterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
280
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

NCT02236156
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Phoenix, Arizona • San Diego, California • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Phase 3 Interventional Results available

A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix

NCT02518594
View directory record Official record
Conditions
Short Cervical Length
Interventions
Vaginal progesterone, Placebo, Arabin Pessary
Drug · Device
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
1,311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 3, 2026, 8:35 AM EDT
Completed Early Phase 1 Interventional

Vaginal lIve Biotherapeutic RANdomized Trial

NCT06135974
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
LC106, LC115, Placebo, Metronidazole Oral
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 3, 2026, 8:35 AM EDT